

ASX ANNOUNCEMENT

Presentation for 2025 Annual General Meeting

26 NOVEMBER 2025

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura** and **Company**) is pleased to release the attached 2025 AGM presentation that will be presented at the 2025 Annual General Meeting of the Company's shareholders to be held as a hybrid meeting at 10.00 am today (Melbourne time) at the offices of K&L Gates, Level 25, South Tower, 525 Collins Street, Melbourne and via Computershare's virtual meeting platform.

**** ENDS ****

VITURA HEALTH LIMITED

ASX: VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU





About Vitura Health Limited (ASX: VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes 430+ therapeutic product and device SKUs within Australia from roughly 60 international and domestic brands.
- www.canview.com.au
Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the nearly 4,500 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.
- www.cortexa.com.au
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- www.cdaclinics.com.au
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- www.cannadoc.com.au
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

**Authorised by**

Robert Iervasi, Chair and Non-Executive Director

Contact**Vitura Health Limited**

Robert Iervasi
Chair
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.



**2025 ANNUAL GENERAL
MEETING AND
COMPANY UPDATE**

WEDNESDAY, 26 NOVEMBER 2025



Disclaimer applying to this presentation

The following disclaimer applies to this presentation (Presentation)

You are therefore advised to read this disclaimer carefully before reading or making any other use of this Presentation or any information contained in this Presentation. This Presentation has been prepared by Vitura Health Limited (**Vitura** or **Company**).

Not investment advice

The information contained in this Presentation is not investment or financial product advice or any recommendation to acquire Shares. This Presentation does not and will not form any part of any contract for the acquisition of Shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation.

Future performance

This Presentation contains forward looking statements and comments about future events, including Vitura's expectations about the performance of its business. Forward looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" and other similar expressions.

You are cautioned not to place undue reliance on any forward-looking statement. While due care and attention has been used in the preparation of forward-looking statements, forward looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends which are based on interpretations of current market conditions. Forward looking statements should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Vitura.

A number of important factors could cause the actual conduct, results, performance or achievement of Vitura to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements. Actual results, performance or achievements may vary materially from any forward-looking statements and the assumptions on which statements are based. Vitura disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise.

The forward-looking statements are based on information available to Vitura as at the date of this Presentation. Except as required by law or regulation, Vitura undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Summary information

This Presentation contains summary information about Vitura and its activities which is current only as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Vitura or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of *the Corporations Act 2001* (Cth.) (Corporations Act).

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Vitura nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.

Not an offer

This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.



Introductions



Robert Iervasi
Chair



Geoff Cockerill
CEO



Tom Howitt
CFO and Company Secretary

AGENDA

- Vision and Mission for FY2026
- Company Overview
- FY2025 at a Glance
- FY2026 Strategy in Action
- FY2026 Priorities
- Q&A

FY2026 VISION AND MISSION

Vision and Mission for FY2026

Vision //

To lead the future of healthcare access in specialty and emerging therapies.

Mission //

To build a connected ecosystem of patients, clinicians, pharmacies and suppliers through a seamless platform that delivers trusted access to specialty and emerging therapies.

COMPANY OVERVIEW

Vitura's Unique Digital Health Ecosystem



Vitura captures value at multiple points, supporting sustainable business growth.

A Growing Portfolio of Interconnected Brands




Company Information (as at 24 November 2025)

Shares On Issue	662,741,837
Market Capitalisation (at 6.6 cents)	\$43.7M
Substantial Shareholders	Charlie Shahin AO (17.28%) Sarah Jansen (13.02%) Guy Headley (7.56%) Jessimine Jansen (7.56%) Cronos Group Inc. (8.33%) Matua Jansen (5.18%)
Board of Directors	Robert Iervasi (Chair) Daniel Birch (NED) Gerard Fogarty AO (NED) Shane Tanner (NED) Rebecca Wilson (NED)



FY2025 AT A GLANCE

FY2025 Financials at a Glance



All amounts are Australian dollars


Q1 FY2026 Key Takeaways

Q1 of FY2026 has started well on several fronts, including:


- Annualised revenue is more than 13% up on the same figure for FY2025
- Normalised OPEX is nearly 8% down against budget forecasts
- Our OPEX efficiency is less than 21%, improved from 24% in FY2025
- While margin pressures remain, we have clear strategies in place to drive margin improvement
- Driving gross profit and further reducing OPEX remains our key focus for Q2 FY2026 and beyond

FY2026 STRATEGY IN ACTION

FY2026 Strategy in Action



Canview – A Recognised Leader in the Market




Doctors on Demand (DoD) – A Leader in Australian Telehealth

- **DoD** was acquired by Vitura in October 2023
- 24/7, 365-day nationwide GP telehealth services
- More than 350 doctors registered on the DoD platform
- Continued strong growth in FY2025:
 - Annualised revenue for July 2025 of \$32 million **UP 26% vs PCP**
 - Total consultation numbers **UP 25% YOY**
 - Record of almost 377,000 consultations in FY2025
 - Daily record of 1,563 consultations achieved in July 2025
- B2B revenue growth continued **UP 37% YOY**
- Further B2B customers acquired post year-end



Acquisitions Driving Growth – Candor and Releaf


- **Candor Medical** was acquired by Vitura in February 2025
- Candor delivered an additional 15,000 active patients
- Forms centrepiece of new “Specialty Clinics” division
- Flora Holdings JV (in which Vitura holds 42.5%) acquired the majority of the assets of **Releaf Group Limited** in November 2024
- Releaf delivered up to 30,000 additional registered patients
- Flora has actively re-engaged with the Releaf patient base
- New medical staff have been onboarded, driving more consults
- Flora JV acquired **Heyday Medical** clinic in May 2025, delivering further active patients



Candor expansion with new website

First visual cue of the activation plan that aims to reset sentiment and build reputation via multiple touchpoints, delivering: **awareness, acquisition, retention and advocacy.**

- Mobile-first optimisation and modern design, addressing key pain points of previous branding
- Improved user experience (UX) and conversion pathways designed to reduce drop-off
- Built with scalable SEO foundations – phased rollout of high-intent landing pages etc. post-launch
- Improved analytics for increased performance visibility



FY2026 PRIORITIES


FY2026 Priorities

Our major priorities for FY2026 are:

- Increasing patient acquisition and retention;
- Producing a consistent supply of quality doctors;
- Scaling our successful Doctors on Demand service;
- Improving margins;
- Technology investment in Canview; and
- Keeping a laser-like focus on OPEX and creating a winning team.

Summary

- Executing well against strategic reset
- Proven delivery and execution in the marketplace
- New acquisitions integrating well and growing
- Medical consulting and service fees rising strongly
- Clinical care quality a benchmark for telehealth
- New verticals enhancing patient healthcare experience
- Diligent cost control improving operational efficiency



QUESTIONS AND ANSWERS